DOV A MD GOLDSTEIN
CIK 1120478 · Chief Financial Officer · last filed 2026-04-24
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$4.51M
Companies
9
Total Filings
62
Lifetime Open-Market Net
-$37.15M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BIOA | Chief Financial Officer | 36,575 | $18.04 | $659.8K | -$531.8K | 7 | 2026-04-24 |
| COYA | Director | 27,557 | $4.74 | $130.6K | $0 | 6 | 2026-01-06 |
| GANX | Director | — | $1.68 | — | $0 | 4 | 2025-06-25 |
| NeuBase Therapeutics, Inc. (NBSE) Delisted | Director | 30,000 | $0.38 | $11.3K | $158.0K | 7 | 2022-09-12 |
| ADMA | Director | 7,500 | $8.21 | $61.6K | $0 | 8 | 2020-05-01 |
| ESPR | Director | 1,162,814 | $3.15 | $3.66M | -$53.53M | 11 | 2018-06-08 |
| MELINTA THERAPEUTICS, INC. /NEW/ (CEMP) Delisted | Director | 95 | — | — | $1.39M | 14 | 2017-03-09 |
| Loxo Oncology, Inc. (LOXO) Delisted | CFO and Treasurer | 3,515,207 | — | — | $5.37M | 2 | 2015-04-03 |
| Durata Therapeutics, Inc. (DRTX) Delisted | Director | 2,019,713 | — | — | $10.00M | 1 | 2012-07-25 |
Recent Filings · Page 2 of 7
62 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-02-20 | BIOA | Grant (A) | — | $0 | EDGAR |
| 2025-01-03 | COYA | Grant (A) | — | $0 | EDGAR |
| 2024-06-26 | GANX | Grant (A) | — | $0 | EDGAR |
| 2024-01-19 | COYA | Grant (A) | — | $0 | EDGAR |
| 2023-06-26 | GANX | Grant (A) | — | $0 | EDGAR |
| 2023-01-04 | COYA | Buy (P) | +10,000 | $0 | EDGAR |
| 2022-09-22 | GANX | Grant (A) | — | $0 | EDGAR |
| 2022-09-12 | NeuBase Therapeutics, Inc. (NBSE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-09-17 | NeuBase Therapeutics, Inc. (NBSE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-21 | NeuBase Therapeutics, Inc. (NBSE) Delisted | Buy (P) | +8,000 | $38.0K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.